Cargando…

Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients

Neutropenia secondary to chemotherapy in breast cancer patients can be life-threatening and there are no biomarkers available to predict the risk of drug-induced neutropenia in those patients. We previously performed a genome-wide association study (GWAS) for neutropenia events in women with breast...

Descripción completa

Detalles Bibliográficos
Autores principales: Bidadi, Behzad, Liu, Duan, Kalari, Krishna R., Rubner, Matthias, Hein, Alexander, Beckmann, Matthias W., Rack, Brigitte, Janni, Wolfgang, Fasching, Peter A., Weinshilboum, Richard M., Wang, Liewei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859084/
https://www.ncbi.nlm.nih.gov/pubmed/29593529
http://dx.doi.org/10.3389/fphar.2018.00158
_version_ 1783307747560783872
author Bidadi, Behzad
Liu, Duan
Kalari, Krishna R.
Rubner, Matthias
Hein, Alexander
Beckmann, Matthias W.
Rack, Brigitte
Janni, Wolfgang
Fasching, Peter A.
Weinshilboum, Richard M.
Wang, Liewei
author_facet Bidadi, Behzad
Liu, Duan
Kalari, Krishna R.
Rubner, Matthias
Hein, Alexander
Beckmann, Matthias W.
Rack, Brigitte
Janni, Wolfgang
Fasching, Peter A.
Weinshilboum, Richard M.
Wang, Liewei
author_sort Bidadi, Behzad
collection PubMed
description Neutropenia secondary to chemotherapy in breast cancer patients can be life-threatening and there are no biomarkers available to predict the risk of drug-induced neutropenia in those patients. We previously performed a genome-wide association study (GWAS) for neutropenia events in women with breast cancer who were treated with 5-fluorouracil, epirubicin and cyclophosphamide and recruited to the SUCCESS-A trial. A genome-wide significant single-nucleotide polymorphism (SNP) signal in the tumor necrosis factor superfamily member 13B (TNFSF13B) gene, encoding the cytokine B-cell activating factor (BAFF), was identified in that GWAS. Taking advantage of these existing GWAS data, in the present study we utilized a pathway-based analysis approach by leveraging knowledge of the pharmacokinetics and pharmacodynamics of drugs and breast cancer pathophysiology to identify additional SNPs/genes associated with the underlying etiology of chemotherapy-induced neutropenia. We identified three SNPs in the hyaluronan mediated motility receptor (HMMR) gene that were significantly associated with neutropenia (p < 1.0E-04). Those three SNPs were trans-expression quantitative trait loci for the expression of TNFSF13B (p < 1.0E-04). The minor allele of these HMMR SNPs was associated with a decreased TNFSF13B mRNA level. Additional functional studies performed with lymphoblastoid cell lines (LCLs) demonstrated that LCLs possessing the minor allele for the HMMR SNPs were more sensitive to drug treatment. Knock-down of TNFSF13B in LCLs and HL-60 promyelocytic cells and treatment of those cells with BAFF modulated the cell sensitivity to chemotherapy treatment. These results demonstrate that HMMR SNP-dependent cytotoxicity of these chemotherapeutic agents might be related to TNFSF13B expression level. In summary, utilizing a pathway-based approach for the analysis of GWAS data, we identified additional SNPs in the HMMR gene that were associated with neutropenia and also were correlated with TNFSF13B expression.
format Online
Article
Text
id pubmed-5859084
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-58590842018-03-28 Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients Bidadi, Behzad Liu, Duan Kalari, Krishna R. Rubner, Matthias Hein, Alexander Beckmann, Matthias W. Rack, Brigitte Janni, Wolfgang Fasching, Peter A. Weinshilboum, Richard M. Wang, Liewei Front Pharmacol Pharmacology Neutropenia secondary to chemotherapy in breast cancer patients can be life-threatening and there are no biomarkers available to predict the risk of drug-induced neutropenia in those patients. We previously performed a genome-wide association study (GWAS) for neutropenia events in women with breast cancer who were treated with 5-fluorouracil, epirubicin and cyclophosphamide and recruited to the SUCCESS-A trial. A genome-wide significant single-nucleotide polymorphism (SNP) signal in the tumor necrosis factor superfamily member 13B (TNFSF13B) gene, encoding the cytokine B-cell activating factor (BAFF), was identified in that GWAS. Taking advantage of these existing GWAS data, in the present study we utilized a pathway-based analysis approach by leveraging knowledge of the pharmacokinetics and pharmacodynamics of drugs and breast cancer pathophysiology to identify additional SNPs/genes associated with the underlying etiology of chemotherapy-induced neutropenia. We identified three SNPs in the hyaluronan mediated motility receptor (HMMR) gene that were significantly associated with neutropenia (p < 1.0E-04). Those three SNPs were trans-expression quantitative trait loci for the expression of TNFSF13B (p < 1.0E-04). The minor allele of these HMMR SNPs was associated with a decreased TNFSF13B mRNA level. Additional functional studies performed with lymphoblastoid cell lines (LCLs) demonstrated that LCLs possessing the minor allele for the HMMR SNPs were more sensitive to drug treatment. Knock-down of TNFSF13B in LCLs and HL-60 promyelocytic cells and treatment of those cells with BAFF modulated the cell sensitivity to chemotherapy treatment. These results demonstrate that HMMR SNP-dependent cytotoxicity of these chemotherapeutic agents might be related to TNFSF13B expression level. In summary, utilizing a pathway-based approach for the analysis of GWAS data, we identified additional SNPs in the HMMR gene that were associated with neutropenia and also were correlated with TNFSF13B expression. Frontiers Media S.A. 2018-03-13 /pmc/articles/PMC5859084/ /pubmed/29593529 http://dx.doi.org/10.3389/fphar.2018.00158 Text en Copyright © 2018 Bidadi, Liu, Kalari, Rubner, Hein, Beckmann, Rack, Janni, Fasching, Weinshilboum and Wang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Bidadi, Behzad
Liu, Duan
Kalari, Krishna R.
Rubner, Matthias
Hein, Alexander
Beckmann, Matthias W.
Rack, Brigitte
Janni, Wolfgang
Fasching, Peter A.
Weinshilboum, Richard M.
Wang, Liewei
Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients
title Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients
title_full Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients
title_fullStr Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients
title_full_unstemmed Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients
title_short Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients
title_sort pathway-based analysis of genome-wide association data identified snps in hmmr as biomarker for chemotherapy- induced neutropenia in breast cancer patients
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859084/
https://www.ncbi.nlm.nih.gov/pubmed/29593529
http://dx.doi.org/10.3389/fphar.2018.00158
work_keys_str_mv AT bidadibehzad pathwaybasedanalysisofgenomewideassociationdataidentifiedsnpsinhmmrasbiomarkerforchemotherapyinducedneutropeniainbreastcancerpatients
AT liuduan pathwaybasedanalysisofgenomewideassociationdataidentifiedsnpsinhmmrasbiomarkerforchemotherapyinducedneutropeniainbreastcancerpatients
AT kalarikrishnar pathwaybasedanalysisofgenomewideassociationdataidentifiedsnpsinhmmrasbiomarkerforchemotherapyinducedneutropeniainbreastcancerpatients
AT rubnermatthias pathwaybasedanalysisofgenomewideassociationdataidentifiedsnpsinhmmrasbiomarkerforchemotherapyinducedneutropeniainbreastcancerpatients
AT heinalexander pathwaybasedanalysisofgenomewideassociationdataidentifiedsnpsinhmmrasbiomarkerforchemotherapyinducedneutropeniainbreastcancerpatients
AT beckmannmatthiasw pathwaybasedanalysisofgenomewideassociationdataidentifiedsnpsinhmmrasbiomarkerforchemotherapyinducedneutropeniainbreastcancerpatients
AT rackbrigitte pathwaybasedanalysisofgenomewideassociationdataidentifiedsnpsinhmmrasbiomarkerforchemotherapyinducedneutropeniainbreastcancerpatients
AT janniwolfgang pathwaybasedanalysisofgenomewideassociationdataidentifiedsnpsinhmmrasbiomarkerforchemotherapyinducedneutropeniainbreastcancerpatients
AT faschingpetera pathwaybasedanalysisofgenomewideassociationdataidentifiedsnpsinhmmrasbiomarkerforchemotherapyinducedneutropeniainbreastcancerpatients
AT weinshilboumrichardm pathwaybasedanalysisofgenomewideassociationdataidentifiedsnpsinhmmrasbiomarkerforchemotherapyinducedneutropeniainbreastcancerpatients
AT wangliewei pathwaybasedanalysisofgenomewideassociationdataidentifiedsnpsinhmmrasbiomarkerforchemotherapyinducedneutropeniainbreastcancerpatients